|Day Low/High||17.85 / 18.45|
|52 Wk Low/High||16.00 / 36.83|
Transactions extend maturities and reduce total debt by approximately 18%
AMAG, ETM, HYH, CRAY and INCY all recently were downgraded by TheStreet's Quant Ratings.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, AVD, BCC, BGSF, CDR, CTRE, DV, LUK, PHX, PRLB, RTIX, SFM, STAY, TRP, WAGE, ZAGG Downgrades: ABCO, ACIW, AMAG, CQP, HDNG, INT, NEWM, RGS, SGEN, SSP, TAC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Luminex, Exelixis, AMAG Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
FDA Decision Anticipated on sNDA filing in the Fourth Quarter 2017
Anticipated U.S. launch in mid-2017
Pacific Biosciences of California, AMAG Pharmaceuticals and Global Blood Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 1,238,470 share increase in total short interest for AMAG Pharmaceuticals, Inc. , to 7,338,003, an increase of 20.30% since 01/13/2017.